Victory Capital Management
IPXL

Victory Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Victory Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,274,813
Closed -$16.9M – 1902
2016
Q4 		$16.9M Buy
1,274,813
+36,023
+3% +$616K 0.04% 606
2016
Q3 		$29.4M Buy
1,238,790
+217,142
+21% +$5.84M 0.08% 433
2016
Q2 		$29.4M Buy
1,021,648
+91,958
+10% +$3M 0.12% 302
2016
Q1 		$29.8M Buy
929,690
+423,452
+84% +$14.9M 0.12% 294
2015
Q4 		$21.6M Sell
506,238
-9,336
-2% -$373K 0.09% 372
2015
Q3 		$18.2M Buy
515,574
+18,965
+4% +$854K 0.07% 412
2015
Q2 		$22.8M Sell
496,609
-141,869
-22% -$6.73M 0.08% 380
2015
Q1 		$29.9M Buy
638,478
+57,843
+10% +$2.3M 0.11% 327
2014
Q4 		$18.4M Buy
+580,635
New +$17M 0.07% 426

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Victory Capital Management's IPXL Position: Q1 2017 in Review

Victory Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 1,274,813 shares — an estimated $16.9M sold.

Victory Capital Management first reported a position in IPXL in Q4 2014 and held it in 9 quarters. The position peaked at $29.9M in Q1 2015. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • Victory Capital Management reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • Victory Capital Management sold 1,274,813 Impax Laboratories, Inc. shares in Q1 2017, an estimated $16.9M.
  • Victory Capital Management first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 9 quarters.
  • Victory Capital Management's Impax Laboratories, Inc. position peaked at $29.9M in Q1 2015.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Victory Capital Management's 13F filing for Q1 2017, filed 10 May 2017.